Regulation 2026/977: Notified Body Timelines and Costs
Introduction
Regulation 2026/977 is the first time the European Commission has told notified bodies, in binding law, how long they may take and how they must price their work. For eight years manufacturers have planned MDR and IVDR certification around guesses: a quotation that grew mid-project, a technical documentation review that stretched past a year, a re-certification that turned into a second initial assessment. The Commission Implementing Regulation (EU) 2026/977 of 4 May 2026 replaces those guesses with maximum timelines, a capped number of clock-stops, a mandatory cost warning and a re-certification procedure that is explicitly not allowed to repeat the original assessment.
None of that removes the hard work from the manufacturer's side. The clocks run on complete applications and solid files, and every weak document burns an interruption from a budget that is now counted. If your EU MDR technical documentation or your IVDR file is not ready on day one, the new rules will simply measure, precisely, how late you are. Plan this together with the EU MDR transition deadlines, because the transitional cut-offs of Regulation 2026/977 interact directly with the certificates you are renewing over the next two years.
This article walks through why the regulation exists, what each article requires, the timelines and interruption budgets phase by phase, the new re-certification logic, the notified body reporting obligations, the transitional dates, and the six manufacturer-side gaps that will waste the benefit.
Table of Contents
- Why the Commission had to legislate notified body behaviour
- What Regulation 2026/977 covers, and what it leaves untouched
- The quotation becomes a document you can plan a budget on
- What the notified body may ask before quoting
- What a compliant quotation must contain
- Regulation 2026/977 maximum timelines, phase by phase
- The initial certification clock
- Planned substantial changes
- Interruptions: the budget that decides your real timeline
- Re-certification without a second initial assessment
- Product certificates under Article 5
- QMS certificates under Article 6
- The decision and the three-month rule
- Notified bodies become measurable: Article 4
- Which of your files the new rules will catch, and when
- Six ways manufacturers will waste the new rules
- Frequently asked questions
- Conclusions
Why the Commission had to legislate notified body behaviour
The MDR and the IVDR already contain detailed requirements for notified bodies. Annex VII of both regulations covers organisation, resources, independence, the conformity assessment process and the final review. What Annex VII never did was fix the commercial and procedural behaviour that manufacturers actually experience: how a quotation is built, how long each step may take, how often the clock can stop, and what a re-certification is supposed to look at. Each notified body filled those gaps with its own interpretation.
The recitals of the regulation say this openly. The Commission observed divergent interpretations by notified bodies of Annex VII requirements, in particular on quotations, completion timelines and re-certification, and noted that the inconsistency disadvantages manufacturers, with small and medium-sized enterprises hit hardest. In practice the divergence showed up as quotations that were impossible to compare, applications rejected for missing information nobody had asked for, technical documentation reviews with no end date, and renewals that re-opened the entire file as if the certificate had never existed.
The instrument chosen matters. This is an implementing regulation, binding in its entirety and directly applicable in every Member State. It is not MDCG guidance that a notified body can treat as good practice, and it is not a Team-NB position paper. A notified body designated under Regulation (EU) 2017/745 or (EU) 2017/746 that ignores these requirements is out of line with its designation conditions, and its designating authority can act on that.
The regulation does not make notified bodies faster by itself. It makes their speed visible and contractually bounded. The manufacturers who gain the most are the ones who already submit complete, coherent files, because they will now be able to hold the notified body to a date.
What Regulation 2026/977 covers, and what it leaves untouched
The operative text is short: nine articles. Article 1 governs quotations. Article 2 sets maximum timelines for initial certification and planned substantial changes. Article 3 caps the number of interruptions. Article 4 obliges notified bodies to monitor duration and cost and to publish an annual report. Articles 5, 6 and 7 define re-certification of product certificates and quality management system certificates and the decision that follows. Article 8 contains transitional provisions and Article 9 sets entry into force and application.
Just as important is what the regulation does not do. It does not change the conformity assessment annexes, the classification rules, the general safety and performance requirements or the clinical evidence standard. It does not set fee levels; it sets how fees must be estimated and when an increase must be announced. It does not create a right to a certificate when a deadline passes: Article 2(4) is explicit that expiry of a maximum timeline, or exhaustion of the interruption budget, is not in itself a sufficient reason for the notified body to refuse a certificate or a change approval. The reverse is equally true. A missed deadline does not hand the manufacturer a certificate.
The regulation applies to notified bodies designated under the MDR and the IVDR, so it covers both device and IVD certification. Where the text differentiates, it does so through the activity rather than the regulation: the product verification timeline applies to the technical documentation assessments that the conformity assessment procedures actually require, which Recital 14 links to class III and class IIb implantable devices, class D IVDs, and the sampling of representative devices for other class IIb and IIa devices, class B and C IVDs, and certain specific IVDs such as companion diagnostics and self-testing devices.
The quotation becomes a document you can plan a budget on
Article 1 attacks the first source of unpredictability: a price that is not really a price. Until now a manufacturer might receive one quotation built on a day rate with no estimate of days, and another built on a lump sum that later grew through change orders. Neither could be compared, and neither could be put into a business plan with any confidence.
What the notified body may ask before quoting
Article 1(1), points (a) to (j), lists the information a notified body may require before issuing a quotation. It covers the identity of the manufacturer and of any authorised representative; the data needed to establish SME status, meaning staff headcount and annual turnover; for each site, the headcount, shifts and activities performed; the suppliers and subcontractors involved in relevant design or manufacturing; a description of the devices with their intended purpose, technologies and risk class; the conformity assessment procedure sought; planned changes; and, for re-certification, the certificates concerned.
The list cuts both ways. It limits what a notified body can demand before it commits to a price, and it tells the manufacturer exactly what to prepare so that the application is complete. The second subparagraph of Article 1(1) adds a practical relief: for changes or re-certification, points (b) to (g) may be waived where the manufacturer confirms that nothing has changed. The intent is that manufacturers stop resubmitting unchanged information for repeat procedures.
What a compliant quotation must contain
Article 1(3), points (a) to (c), defines the content. The quotation must give an estimate of the overall costs, split between the quality management system assessment and the technical documentation assessment, and it must include the typical costs of surveillance and unannounced audits. It must identify potential additional costs. And it must give estimated timelines. Hourly fees for additional costs are acceptable only where the duration of the activity genuinely cannot be predicted.
Article 1(4) closes the loop. Where costs are expected to rise by more than 10% over the quotation, the notified body must warn the manufacturer in advance and give reasons. That single provision changes the negotiation. A budget overrun discovered at invoice stage is now a breach of procedure, not a commercial surprise.
One gap remains. The regulation sets no deadline for issuing the quotation itself. The 30-day clock in Article 2 starts from a complete application, not from the first enquiry, so a notified body that is slow to quote is not caught by the timelines. Manufacturers should ask for the quotation lead time in writing as part of their own supplier selection.
Regulation 2026/977 maximum timelines, phase by phase
Article 2(1) sets the principle: the notified body and the manufacturer agree the shortest feasible timeline for each activity, taking into account the range and type of devices, their characteristics, their risk class and the activities required. The maximum timelines in the rest of Article 2 are ceilings, not targets. A notified body that quotes the maximum for a single class IIa device with one site and one technology is following the letter of the regulation and ignoring its first paragraph.
The initial certification clock
Article 2(2) defines four phases. Under point (a), application review and contract signature may take at most 30 days from receipt of the complete application to signature. Under point (b), the quality management system audit may take at most 120 days, measured from the first activity of the audit programme to the completion of the final review under Section 4.7 of Annex VII. Under point (c), product verification, meaning the technical documentation assessment, may take at most 90 days for each device or representative device, again up to the final review. Under point (d), the decision and certification, including entry of the certificate in EUDAMED, may take at most 20 days from the day after the last relevant final review.
The last subparagraph of Article 2(2) matters more than it looks. Unless otherwise agreed, the audit and the product verification both start on the day after contract signature, and when the procedure is Annex IX they must be conducted in parallel, with the technical documentation findings feeding the audit programme. On paper, a straightforward initial certification therefore has a notified body time budget of roughly 30 plus 120 plus 20 days, with the 90-day technical documentation assessment absorbed inside the audit window. That is around 170 days of notified body time before interruptions. It is not 170 days of calendar time, for reasons the next section explains.
The text speaks only of days. It does not say working days. Until the Commission or the MDCG says otherwise, plan as if the notified body will read the term in the way least favourable to your launch date, and agree the counting convention in the contract.
Planned substantial changes
Article 2(3) applies the same logic to changes notified to the notified body. Under point (a) the notified body has 30 days to review the planned substantial change and decide whether further assessment is needed. Under point (b), where additional assessment is needed, it has 90 days to carry it out. Under point (c), it has 20 days to issue the certificate supplement. If the change is so significant that a new conformity assessment procedure is required, the initial certification timelines apply instead.
For manufacturers who live on iterative design, especially software and connected devices, this is the most valuable part of the regulation. A change that used to sit in a queue with no visibility now has a defined decision point at 30 days. Build your change control so that every substantial change notification arrives with its impact assessment, updated risk analysis and verification evidence already attached, and the 30-day decision becomes a realistic planning milestone.
✦ EU MDR Technical Documentation Kit · Regulation (EU) 2017/745
Start the 90-day clock with a file that does not burn interruptions.
Product verification under Regulation 2026/977 allows four interruptions, and a thin technical file can use them all in the first round. The kit gives you the Annex II and Annex III structure, GSPR checklist and supporting templates, so the notified body assesses evidence instead of asking for it.
✓ Structured on MDR Annex II and Annex III
✓ GSPR checklist ready for evidence mapping
✓ Editable Word templates
Interruptions: the budget that decides your real timeline
Maximum timelines would mean little if a notified body could stop the clock indefinitely. Article 3 caps the number of interruptions per phase. Under Article 3(1), application review allows one interruption, the quality management system audit allows four, product verification allows four, the review of planned substantial changes under Article 2(3)(a) and (b) allows five in total, the re-certification reviews under Articles 5 and 6 allow three in total, and the certificate verification steps, meaning the decision phases under Article 2(2)(d), Article 2(3)(c) and Article 7(2), allow one.
Multi-site manufacturers get an adjustment. For each additional site covered by the quality management system that is audited on-site, two further interruptions are added to the audit budget. An interruption starts when the manufacturer is informed of the non-compliance or of the justified request for information, and it ends on the day after the notified body receives the response.
Two further rules shape the arithmetic. Under Article 3(3), time spent waiting for an opinion from the European Medicines Agency, a competent authority, an expert panel or an EU reference laboratory is treated as a separate interruption that does not count against the limits. That matters for drug-device combinations, devices incorporating human blood derivatives, class III implantables going through the clinical evaluation consultation procedure, and class D IVDs requiring EU reference laboratory testing. Under Article 3(4), extending an interruption requires a justified reason and written agreement.
Now read the cap the other way round. The regulation limits the number of times the notified body can stop the clock. It does not shorten the time you take to answer. Every day the manufacturer spends producing a missing biocompatibility justification or a corrected clinical evaluation report is a day outside the 90-day window but inside your launch plan. The manufacturers who will see certificates in five or six months are the ones whose files survive the first review round with few or no questions.
Treat each interruption as a finding. Four interruptions in product verification means four rounds of questions, and each round costs you weeks of calendar time even though it costs the notified body nothing on its clock.
Re-certification without a second initial assessment
Articles 5 to 7 address the complaint that has defined the MDR transition: renewals that behave like first certifications. The Recitals state the principle plainly. Re-certification should be predictable and should not repeat the initial assessment. It should focus on what happened during the certificate's life: post-market surveillance, changes, the evolution of the state of the art, updates to the risk analysis, surveillance results, sampling and the closure of non-compliances.
Product certificates under Article 5
For certificates covering technical documentation, Article 5 sets out what the manufacturer provides: information on changes, the latest periodic safety update report, field safety corrective actions, changes in the benefit-risk determination, updates to the state of the art and the latest clinical evaluation report or performance evaluation report. The manufacturer must also list changes that were not notified because they were made to meet new requirements or to reflect new scientific findings, identifying the basis for each one.
The notified body then has 90 days to assess the package. Its review is defined: whether the post-market data, the state of the art and the updated risk analysis are consistent with each other; whether earlier non-compliances have been resolved; whether conditions attached to the certificate remain valid; whether the scope is still correct; and the final review. This is where your EU MDR post-market surveillance system either carries the renewal or sinks it. A PSUR that reports a signal the risk management file never absorbed is exactly the inconsistency Article 5 tells the reviewer to look for.
QMS certificates under Article 6
For quality management system certificates, Article 6 gives the notified body 90 days to verify that the audit programme covered the scope over the certification cycle, the results of surveillance audits, the audit programme and the sampling plan, the resolution of non-compliances, the validity of conditions, the scope and the final review. The point is that a well-run surveillance cycle should already contain the evidence. If your surveillance audits have closed cleanly and your corrective actions were verified for effectiveness, the renewal becomes a documentary confirmation. If they did not, the renewal is where open findings accumulate into a decision problem. A disciplined ISO 13485 CAPA process is the cheapest re-certification preparation there is.
The decision and the three-month rule
Article 7 limits the re-certification to the review of the documents described in Articles 5 and 6. Under Article 7(2), the decision and the re-issue of the certificate, including the EUDAMED entry, must follow within 20 days of the final review. Article 7(3) adds a timing rule that protects the notified body's planning as much as the manufacturer's: where the decision is taken earlier than three months before the certificate expires, the 20-day period starts three months before expiry rather than at the final review.
The practical message is to start early. Submit the Article 5 package with enough lead time for a 90-day review, up to three interruptions and your own response time, and you land the decision inside the final three months before expiry with a margin. Submit late and the regulation gives you no protection against a certificate gap.
✦ MDR Complete Bundle · Regulation (EU) 2017/745
Arrive at re-certification with a file that tells one consistent story.
Article 5 asks the notified body to test your PMS data, risk analysis, state of the art and clinical evaluation against each other. The bundle brings the technical documentation, risk management, clinical and post-market documents together, so they are written to agree from the start.
✓ Technical documentation, risk, clinical and PMS in one set
✓ Cross-referenced templates built for MDR conformity assessment
Notified bodies become measurable: Article 4
Article 4 is the provision with the longest tail. Under Article 4(1) to (3), every notified body must establish, within its own quality management system, a process to monitor the effective duration and the costs of its conformity assessment activities. The metrics include, at minimum, the percentage of activities completed within the maximum timelines, the median duration from application to certification and the median total cost of completed procedures.
Under Article 4(4), by 30 April of each year the notified body must publish a report on its website and send it to its designating authority and to the Commission. Article 4(4) applies from 1 January 2028, so the first published reports will appear in 2028.
For the first time manufacturers will be able to compare notified bodies on numbers the bodies themselves are obliged to publish, rather than on anecdote and conference gossip. That changes notified body selection from a capacity question, who will take my file, into a performance question, who delivers. It also gives competent authorities and the Commission a data set to supervise against. A notified body that publishes a low on-time percentage will have to explain it to its designating authority.
Which of your files the new rules will catch, and when
Article 9 provides that the regulation enters into force on the twentieth day after publication in the Official Journal and applies from 25 February 2027, with the exception of Article 4(4), which applies from 1 January 2028. Article 8 then carves out ongoing work, and these carve-outs decide whether a given procedure in your portfolio benefits.
| Provision | Applies to | Does not apply to | Source |
|---|---|---|---|
| Articles 1 to 3 (quotations, timelines, interruptions) | Procedures under written agreements signed on or after 25 February 2027 | Procedures under written agreements signed before 25 February 2027 | Art. 8(1) |
| Article 4(1) to (3) (monitoring) | Procedures under written agreements signed after 25 May 2027 | Agreements signed up to that date | Art. 8(2) |
| Article 4(4) (annual report) | From 1 January 2028; report by 30 April each year | — | Art. 9 |
| Articles 5 to 7 (re-certification) | Certificates expiring on or after 25 November 2027 | Re-certification of certificates expiring before 25 November 2027 | Art. 8(3) |
Two decisions follow from the table. First, if you are about to sign a new contract with a notified body for an initial certification, a new device or a scope extension, the signature date determines whether Articles 1 to 3 protect you. A contract signed in January 2027 stays outside the new quotation, timeline and interruption rules for its whole life. If the project can wait, sign on or after 25 February 2027; if it cannot, negotiate equivalent timelines and a cost-increase warning into the contract voluntarily, using the regulation as the reference.
Second, map your certificate expiry dates. Certificates expiring from 25 November 2027 onwards will be renewed under Articles 5 to 7. Given the volume of MDR and IVDR certificates issued in the first wave, a large share of the market will hit re-certification under the new rules, and the transition deadlines for legacy devices under both the IVDR and the MDR will compete for the same notified body capacity. Your renewal package should be ready earlier than you think.
Six ways manufacturers will waste the new rules
The regulation shifts accountability onto the notified body, but only for what happens on the notified body's side of the table. The gaps below are on the manufacturer's side, and each one either consumes the interruption budget or keeps a procedure outside the new rules altogether.
The first is the incomplete application. The 30-day clock in Article 2(2)(a) runs from a complete application. A manufacturer that sends a partial data set has not started anything. Freeze the Article 1(1) information before you ask for a quotation: legal entities, SME data, sites and shifts, critical suppliers, device list with intended purpose and class, and the procedure you are applying for.
The second is the weak technical file. Four interruptions in product verification sounds generous until a reviewer opens a file with an unmapped GSPR checklist, a risk management file that does not trace to the instructions for use and a clinical evaluation built on equivalence that cannot be demonstrated. Each of those is a round of questions. Review the file internally against the questions a reviewer will ask before submission.
The third is arriving at renewal without a coherent post-market story. Article 5 directs the reviewer to the consistency between PMS data, the state of the art and the updated risk analysis. A PSUR and a clinical evaluation report that contradict each other are the fastest way to spend the three re-certification interruptions.
The fourth is signing the contract at the wrong moment, as described above. The fifth is failing to list changes made to meet new requirements or scientific findings, which Article 5 now expects to see identified with their basis; keep a change log organised by certificate, not only by design project. The sixth is ignoring the notified body reports once they exist. From 2028 the numbers are public, and they belong in your supplier evaluation of the notified body as much as any audit of a critical supplier, a habit your internal audit programme can already support.
✦ Complete catalogue
Find the documentation you need — instantly.
Technical documentation, risk management, clinical, IVDR, software and QMS kits, built to the structure notified bodies review against.
✓ EU MDR and EU IVDR documentation kits
✓ ISO 13485, risk management and IEC 62304 kits
Frequently asked questions
What is Regulation 2026/977?
Regulation 2026/977 is a Commission Implementing Regulation of 4 May 2026 laying down uniform quality management and procedural requirements for conformity assessment activities carried out by notified bodies designated under the MDR and the IVDR. It covers quotations, maximum timelines, interruptions, monitoring and reporting, and re-certification.
When does Regulation 2026/977 apply?
It applies from 25 February 2027. The annual notified body report under Article 4(4) applies from 1 January 2028. Articles 1 to 3 do not apply to procedures under written agreements signed before 25 February 2027, and Articles 5 to 7 do not apply to certificates expiring before 25 November 2027.
What are the maximum notified body timelines under Regulation 2026/977?
Application review and contract signature 30 days, quality management system audit 120 days, product verification 90 days per device or representative device, and decision and certification including EUDAMED 20 days. Planned substantial changes have 30, 90 and 20 days. Re-certification reviews have 90 days and the decision 20 days.
Can a notified body refuse a certificate because the timeline expired?
No. Article 2(4) states that expiry of the maximum timelines or use of the maximum number of interruptions is not in itself sufficient reason to refuse a certificate or a change approval. Equally, a missed deadline does not entitle the manufacturer to a certificate.
How many times can a notified body stop the clock?
One interruption for application review, four for the QMS audit plus two for each additional site audited on-site, four for product verification, five in total for planned substantial changes, three in total for re-certification reviews and one for each decision step. Waiting for EMA, authority, expert panel or EU reference laboratory input does not count.
Does Regulation 2026/977 set notified body fees?
No. It does not fix fee levels. It requires quotations to estimate overall costs split between QMS and technical documentation assessment, including surveillance and unannounced audits, to identify potential additional costs, and to warn the manufacturer in advance, with reasons, of any increase above 10%.
Conclusions
Regulation 2026/977 turns notified body performance into something you can contract for and measure. Use it in three steps. Map every certificate expiry date against 25 November 2027 and every planned contract against 25 February 2027, so you know which procedures the new rules will cover. Prepare the Article 1(1) data set and a review-ready technical file before you ask for a quotation, because the clocks only run on complete applications and every weak document costs an interruption. And from 2028, choose and evaluate your notified body on the numbers it is now obliged to publish.
The EU MDR Technical Documentation Kit on MD Regulatory includes the Annex II and Annex III structure, the GSPR checklist and the supporting templates, all aligned with MDR requirements and immediately deployable in an existing ISO 13485 quality management system, so the notified body's 90 days are spent assessing evidence rather than requesting it.
Related articles
- EU MDR Technical Documentation
- EU MDR Transition Deadlines
- EU MDR Post-Market Surveillance
- IVDR Explained
Official text: Commission Implementing Regulation (EU) 2026/977 on EUR-Lex.